Buy Generic Duphaston Online

Generic Duphaston Information

Introduction

Duphaston is a synthetic progestogen containing the active compound dydrogesterone. It belongs to the therapeutic groups of best‑selling women's health medicines and is widely used in the United Kingdom for conditions that require progesterone activity. The medication is manufactured by several licensed pharmaceutical companies and is listed in the British National Formulary (BNF) as a treatment for progesterone‑related disorders, infertility associated with luteal‑phase deficiency, endometrial preparation for assisted reproduction, and as part of combined hormone replacement therapy (HRT) in post‑menopausal women.

What is Duphaston?

Duphaston is a tablet formulation of dydrogesterone, a non‑steroidal progestogen that mimics the activity of natural progesterone on the progesterone receptor (PR). The drug was first developed in the 196s by Schering AG and has since been marketed worldwide under various brand names, including Duphaston®, Dydrogesic® and Progyl® (the latter being a European brand). In the United Kingdom it is prescribed in doses ranging from 5 mg to 40 mg per day, depending on the indication. The tablets contain inert excipients such as lactose monohydrate, maize starch and magnesium stearate, which are generally well tolerated.

How Duphaston Works

Dydrogesterone binds selectively to the intracellular progesterone receptor, initiating a cascade of gene transcription that reproduces the natural actions of endogenous progesterone. The key therapeutic effects are:

• Endometrial transformation: Conversion of the proliferative endometrium into a secretory state, essential for implantation and maintenance of early pregnancy.
• Inhibition of ovulation: When administered in the luteal phase, it prevents premature luteolysis and sustains corpus luteum function.
• Anti‑estrogenic activity in the breast and uterus: Reducing estrogen‑driven proliferation and mitigating symptoms of estrogen excess.

Pharmacokinetic data from the European Medicines Agency (EMA) indicate that dydrogesterone is rapidly absorbed after oral administration, reaching peak plasma concentrations within 1–2 hours. The drug is metabolised primarily by hepatic CYP3A4 to an inactive hydroxy‑dydrogesterone, with a terminal half‑life of approximately 5–7 hours. Steady‑state concentrations are achieved after 2–3 days of regular dosing, supporting its use in short‑term luteal support as well as longer‑term HRT regimens.

Conditions Treated with Duphaston

The following indications are approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and reflected in the BNF:

• Luteal‑phase deficiency (LPD) and infertility: Duphaston supports the luteal phase in assisted reproductive technology (ART) cycles and natural cycles where progesterone secretion is inadequate.
• Menstrual disorders: Treatment of irregular or absent periods (amenorrhoea) and pre‑menstrual syndrome (PMS) where progesterone deficiency is implicated.
• Threatened miscarriage: Supplementation in early pregnancy (≤ 12 weeks) when progesterone levels are low, to reduce the risk of miscarriage.
• Endometriosis: Hormonal suppression of ectopic endometrial tissue, alleviating pain and lesion progression.
• Hormone replacement therapy (HRT): Combined with estrogen in post‑menopausal women to prevent endometrial hyperplasia and reduce vasomotor symptoms.

In the UK, approximately 1 % of women of reproductive age are diagnosed with LPD, while endometriosis affects an estimated 10 % of women, underscoring the clinical relevance of a well‑tolerated progestogen such as Duphaston.

Who is Duphaston For?

Duphaston is prescribed for adult women who require supplemental progesterone activity for one or more of the following reasons:

• Women undergoing in‑vitro fertilisation (IVF) or other ART procedures who need luteal support.
• Patients with documented luteal‑phase insufficiency, recurrent early pregnancy loss of gestation, or unexplained infertility linked to progesterone deficiency.
• Women with chronic menstrual irregularities, heavy or prolonged bleeding, or severe pre‑menstrual symptoms where a progestogen is indicated.
• Individuals with endometriosis in whom hormonal suppression is part of a multimodal treatment plan.
• Post‑menopausal women receiving estrogen therapy who need progestogenic protection of the endometrium.

Contra‑indications include: known hypersensitivity to dydrogesterone or any tablet excipient, uncontrolled hypertension, active thromboembolic disease, hepatic impairment, and current pregnancy when the indication is not threatened miscarriage. Caution is advised in patients with a history of breast cancer, severe migraines with aura, or unexplained vaginal bleeding.

Risks, Side Effects, and Interactions

Common

• Nausea and vomiting – usually transient and dose‑related.
• Breast tenderness or swelling – may mimic early pregnancy changes.
• Headache – mild to moderate, often resolves with continued therapy.
• Mild abdominal discomfort or bloating – reflects uterine activity.

Rare

• Mood changes – including irritability or depressive symptoms, reported in < 1 % of users.
• Skin reactions – such as rash, pruritus or urticaria.
• Altered lipid profile – modest increases in triglycerides observed in some long‑term users.

Serious

• Thromboembolic events – deep‑vein thrombosis or pulmonary embolism, particularly in women with pre‑existing risk factors.
• Severe hepatic impairment – jaundice or marked elevation of liver enzymes.
• Allergic anaphylaxis – extremely rare but requires immediate medical attention.

Drug–Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir) can increase dydrogesterone plasma levels, potentially enhancing side‑effects.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine, St. John’s Wort) may reduce therapeutic efficacy by accelerating metabolism.
• Anticoagulants (warfarin, direct oral anticoagulants) – progestogens can theoretically increase clotting risk; monitoring of INR or clinical status is advised.
• Anticonvulsants – some agents (phenobliv) may alter hormone metabolism, requiring dose adjustment.

Patients should disclose all concomitant medications, including over‑the‑counter and herbal products, to their healthcare professional before initiating Duphaston.

Practical Use: Dosing, Missed Dose, Overdose

Standard dosing ranges (UK guidelines):

• Luteal‑phase support: 10 mg orally twice daily, beginning after ovulation or embryo transfer and continuing until at least 10 weeks gestation.
• Menstrual regulation: 10 mg once daily for 5 days each month, or 20 mg daily for 10 days in a cyclic regimen, depending on the clinical protocol.
• Threatened miscarriage: 10 mg orally twice daily until a viable pregnancy is confirmed (usually 6–8 weeks).
• HRT: 5 mg orally once daily in combination with estrogen.

Missed dose:
If a dose is missed by less than 12 hours, take it as soon as remembered and continue the regular schedule. If more than 12 hours have elapsed, skip the missed dose and resume the next scheduled dose; do not double‑dose.

Overdose:
Symptoms: nausea, vomiting, dizziness, or severe headache.
Management: immediate medical evaluation is recommended. Supportive care, including gastric lavage or activated charcoal, may be employed in a hospital setting. No specific antidote exists.

Precautions:

• Take tablets with a glass of water; food does not significantly affect absorption.
• Alcohol does not alter efficacy but excess consumption may exacerbate hepatic side effects.
• Patients with renal or hepatic impairment should be monitored closely; dose reduction may be required.

Buying Duphaston from Our Online Pharmacy

Duphaston is available for purchase through our online pharmacy in the UK. The service offers:

• Affordable pricing: We source the medication near manufacturer cost, passing savings directly to the patient.
• Verified quality: All tablets are supplied by licensed overseas manufacturers that meet EU‑GMP standards and are inspected by independent third‑party labs.
• Guaranteed delivery: Discreet, reliable shipping with options for 7‑day express service or standard airmail (approximately 3 weeks to most UK addresses).
• International access: As a pharmacy broker service, we work with overseas licensed pharmacies to provide medications that may have limited local availability, while maintaining strict privacy protections.

Patients who encounter difficulties obtaining Duphaston through conventional UK pharmacies—due to stock shortages, insurance constraints, or geographic limitations—can benefit from the convenience and cost‑effectiveness of our platform. All orders are processed in compliance with UK import regulations for personal use, and we ensure that packaging is unmarked and confidential.

FAQ

• What is the appearance of a Duphaston tablet?
  Duphaston tablets are round, white to off‑white, and marked with the dosage strength (e.g., “10 mg”) imprinted on one side. The tablets are film‑coated to facilitate swallowing.

• Can Duphaston be stored in a refrigerator?
  No cold storage is required. The medication should be kept at a controlled room temperature (15 °C–25 °C), protected from moisture and direct sunlight.

• Are there any dietary restrictions while taking Duphaston?
  There are no specific food interactions, but excessive alcohol intake can increase hepatic stress. A balanced diet supports overall reproductive health and is recommended.

• How long does a typical Duphaston shipment take to arrive in the UK?
  Standard airmail delivery generally arrives within 2–3 weeks, while express shipping can be received in 5–7 days, depending on customs processing.

• Is lactose present in Duphaston tablets?
  Yes, lactose monohydrate is used as an excipient. Patients with severe lactose intolerance should discuss alternatives with their clinician.

• Can Duphaston be used during breastfeeding?
  Limited data suggest minimal transfer into breast milk. However, clinicians usually advise postponing progestogen therapy until after the initial postpartum period unless benefits outweigh potential risks.

• What is the difference between Duphaston and micronised progesterone tablets?
  Dydrogesterone (Duphaston) is a synthetic progestogen with a selective PR affinity and a more favourable side‑effect profile, whereas micronised progesterone is a natural hormone that may cause more sedation and has a different metabolic pathway.

• Does Duphaston affect hormone‑based contraception effectiveness?
  Duphaston is not a contraceptive and does not provide reliable protection against pregnancy. It should not be used as a substitute for approved birth control methods.

• Are there any special import rules for Duphaston when ordering from abroad?
   Personal importation of a three‑month supply of prescription medicines for personal use is permitted in the UK, provided the medication is for a genuine medical need and the buyer holds a valid prescription. Our pharmacy ensures compliance with these regulations.

• Has Duphaston been studied in large clinical trials?
  Yes. Multiple randomized controlled trials, including the European Dydrogesterone Study Group (EDSG) trials, have demonstrated its efficacy in luteal support for IVF and in reducing miscarriage rates in women with luteal‑phase deficiency.

• Is there a known difference between Duphaston formulations sold in the EU versus the UK?
  Formulation composition is essentially identical; however, packaging and labelling comply with the respective regulatory authority (MHRA for the UK, EMA for the EU).

• Can Duphaston cause a positive result on a pregnancy test?
  No. Dydrogesterone does not contain the hormone hCG, which is measured by pregnancy tests. Positive results reflect endogenous hCG production.

Glossary

Progesterone receptor (PR)

A nuclear receptor that, when activated by progesterone or progestogens, regulates genes involved in endometrial development, pregnancy maintenance, and menstrual cycle control.

Luteal‑phase deficiency (LPD)

A condition in which the corpus luteum fails to produce sufficient progesterone after ovulation, leading to an unstable endometrium and potential infertility or early pregnancy loss.

Endometrium

The inner lining of the uterus that thickens under estrogen influence and becomes secretory under progesterone, providing a receptive environment for embryo implantation.

CYP3A4

A major liver enzyme that metabolises many drugs, including dydrogesterone; its activity can be increased or decreased by other substances, altering drug concentrations.

⚠️ Disclaimer

The information provided about Duphaston is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Duphaston for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.